From the blog

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Primary Outcome Measures Number of Patients who Experience Dose-Limiting Toxicity Number of patients who experience a treatment-related adverse event Objective response rate (ORR) Duration of response (DOR) Progression free survival (PFS) Overall survival (OS) Secondary Outcome Measures Area under the plasma concentration versus time curve (AUC) Time to achieve maximal[…]

Read More »

Immunotherapy to Treat Pleural Mesothelioma

Malignant pleural mesothelioma is a rare and very aggressive cancer with a poor outlook. One cancer treatment has brought hope though. The treatment is known as immune checkpoint inhibitors. There is potential for better outcomes when patients are given this treatment. A new article in Open Respiratory Archives provides a[…]

Read More »

Johnson & Johnson’s Talc Settlement Proposal Denied

A United States Bankruptcy Judge from the Southern District of Texas has denied Johnson & Johnson’s $10 billion baby powder settlement proposal. This is the third time J&J has tried a bankruptcy strategy and failed. If approved, more than 60,000 ovarian cancer lawsuits would have been ended. The company estimated[…]

Read More »

Hemithoracic Arc Radiotherapy Post Pleural Decortication

Primary Outcome Measures Acute Radiation Toxicity late radiation toxicity Inclusion Criteria Evidence of metastatic disease. Underwent Pleural decortication. Able to provide informed consent. Exclusion Criteria Poor pulmonary function tests. Recurrent or palliative cases. Inability to attend full course of Radiotherapy or follow up visits.

Read More »

Asbestos Delays Wildfire Cleanup

Asbestos testing with certified asbestos consultants and other experts has been ongoing since two wildfires, Eaton and Palisades, blazed across California in 2025. More properties that were burned in the Eaton Fire in Altadena, California have tested positive for asbestos, according to Senator Adam Schiff. The U.S Army Corps of[…]

Read More »

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)

Primary Outcome Measures Diagnostic Performance Secondary Outcome Measures Location biopsy Staging Patient Management Uptake Values Changes uptake parameters due to anticancer treatment Correlate immunohistochemistry Incidental findings Safety Evaluation FAPI-injection Overall survival Recurrence/Progression Free Survival Response evaluation Interobserver reliability Inclusion Criteria Patients with pleural lesions suspicious of pleural mesothelioma and referred[…]

Read More »

CAR-T Cell Therapy for Mesothelioma

Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. With the disease being rare, there are limited treatment options for the disease. This is especially true for elderly patients. They can struggle with conventional therapies due to their age and health problems. One therapy known as Chimeric[…]

Read More »

Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE VariaTionS (MAGNETS)

Primary Outcome Measures the comparison of prevalence of germline mutations in MPM patients vs asbestos exposed healthy subjects Secondary Outcome Measures Secondary aim will be the comparison of overall survival (OS) according to mutational status in MPM patients. Inclusion Criteria Inclusion Criteria Cohort A: Patient with a documented diagnosis of[…]

Read More »

Asbestos Tailings Could be Used to Help the Environment

An abandoned asbestos mine in Baie Verte, in Newfoundland, is expected to have a significant environmental remediation project. BAIE Minerals, a company that specializes in mineral upcycling, plans to transform asbestos into usable resources by utilizing a new, innovative process. The Advocate Mine began operation in 1963, supplying asbestos for[…]

Read More »